Read the latest news from the membership of NewYorkBIO, including legislative developments, industry and academic research news, and updates on events.
NewYorkBIO News  
January 2016

From the Executive Director

NewYorkBIO is pretty excited about the new year.  After all, there is essentially a microboom in companies moving in and moving up in New York. Our company news-briefs this month highlight the new life in New York life sciences.
More young companies are choosing New York as home, and more established companies, Lycera, Cellectis among them, are moving here and expanding. Petra's opening and the launch of Versilant Ventures's Highline Therapeutics are key signs of growth; clearly, New York's VCs and funding companies are spinning out new companies. 

Hopefully, the (long-awaited) City of New York Early-Stage Life Sciences Fund will soon have an announcement or two. 
Still, along with this good news, I remain concerned about the out-balanced ratio between New York's high level of NIH funding and its surprisingly small level of VC funding.  Proportion is crucial to healthy growth, and city and state need to work together to support and build this industry.
Speaking of funding, NewYorkBIO is heading to San Francisco next week for the JP Morgan Healthcare Conference, and I look forward to seeing you at some of our events there.  First, we have partnered with a group of other great state biotech associations to host hundreds of conference attendees at our annual NewYorkBio and Friends Wine Reception. You can also find me hosting the Biotech Showcase 2016.  And, we are very pleased to offer our members a complimentary one-on-one meeting space at the JP Morgan Conference, compliments of our sponsors, Frommer, Lawrence & Haug and Fitzpatrick. Hope to see you there!

Have a happy 2016!

Nathan Tinker
Executive Director

Like us on Facebook
Follow us on Twitter
Save from 15% to 33% on a wide range of  select FedEx® services , with additional discounts for high-volume shippers. Whether you're shipping biologics, pharmaceuticals or lab samples, you can count on FedEx®.

PolicyPublic Policy & Advocacy

  • Governor Cuomo has launched a new $5 million venture capital competition for biotechnology startups, stimulating growth in the biotech industry. 
  • To stimulate further growth in the bio-science industry in New York, the State is launching a broad based investment initiative focused on the bio-science industry. The centerpiece of the initiative will be the creation of a multi-year venture capital competition. This competition will focus on selecting the most promising startups and assisting them in commercializing technologies developed within New York State universities and research labs. Annual prizes totaling $1 million will be awarded to promising Bio-Science companies following each round of competition.
  • ATTENTION NYC BIOTECH COMPANIES: Refundable NYC Tax credit available to Biotech Companies: must file by  JANUARY 15, 2016NewYorkBIO began advocating for an New York City Biotechnology Tax Credit in 2007, and we are very pleased that the credit has again been extended for two years! For the tax year ended December 31, 2015 taxpayers that are qualified emerging technology companies (QETC), engage in biotechnologies, and meet eligibility requirements may claim a tax credit against the New York City general corporation tax, business corporation tax, or unincorporated business tax for amounts paid or incurred for certain facilities, operations, and employee training.

Registration is  open for the 2016 BIO CEO & Investor Conference
NewYorkBIO is proud to be the Local Co-Host of the BIO CEO & Investor Conference!  Now in its 18th year, the BIO CEO & Investor Conference, happening February 8-9 in New York City, is the largest investor conference focused on established and emerging publicly traded and select private biotech companies.    View the list of 2015 attendees, and register for 2016 .

And don't forget to join us as we kick off the BIO CEO & Investor Conference for NewYorkBIO Pub Night "Upstairs" on Sunday, Feb 7.  Information and registration here
TodayNew York Life Sciences Today

A Visit With Gilda's Club New York City
This month, NewYorkBIO News Editor MV Lamothe asks Gilda's Club New York City CEO Lily Safani about about her outlook for 2016. 

The mission of Gilda's Club New York City is to Support, Educate, and Empower Cancer Patients and Their Families. Their free comprehensive cancer program includes support groups, educational lectures and workshops for everyone impacted by cancer - men, women, teens, and children. Since 1995, more than 11,000 individuals and families have visited the Clubhouse in the West Village in Manhattan or one of the off-site locations with hospital partners around New York City. Today, with more than 4,600 members, Gilda's Club programs provide support and networking groups, educational lectures, workshops and social activities for cancer patients, their loved ones, and those who are bereft.

NewYorkBIO: NewYorkBIO is so fortunate that Gilda's Club New York City is a member of the Association. Your organization has had a busy year. Can you tell us some of the highlights of Gilda's Club events from 2015?

Lily Safani: For Gilda's Club New York City, 2015 was a milestone year -- 20 years of free cancer support.  We opened our signature Red Door on June 9, 1995, and have never wavered from our mission to provide free support and education to cancer patients and their families.  Moving forward, we are dedicated to going beyond our beautiful Clubhouse on West Houston Street and our Painting the Town Red with our newer Gilda Comes To You offsite model. There are over 100 people a day who are newly diagnosed with cancer in New York City alone. The Institute of Medicine has projected a 45% increase in cancer by 2035. Unfortunately, the need for our services is growing not diminishing.
In 2015, our membership grew 29% due to the expansion of Gilda Comes To You, which brings free cancer support where it is needed most - to the underserved communities of New York City.  With the generous support of corporations, foundations and individual donors who attend our many special events this year we have been able to expand our reach to meet the growing need for our services.  These events include Gildafest'15, our first comedy event honoring Amy Poehler; our benefit luncheon Celebrating Women Working & Living with Cancer; the Gildies; our Gilda Marathon and Bike Teams; and our signature gala held in November, which raised over $1.7 million. 

NewYorkBIO: With so much growth during 2015, what is Gilda's Club NYC looking forward to in the New Year?

Lily Safani: Where are we going in 2016? Today, 30% of our program is at hospital partners in the Bronx, Brooklyn, Manhattan, and Queens.  The money we raised in 2015 will help us serve more cancer patients and their families beyond our Red Door - wherever they live or receive treatment - Gilda Will Come To You.  With our increased funding, we hope to Paint the Town Red and expand our Gilda Comes To You program so no one has to face cancer alone.

Gilda's Club New York City
195 West Houston Street
New York, NY 10014

News From NewYorkBIO

NewYorkBIO Offers Meeting Space at JP Morgan Conference
Finding a quiet place for a meeting during JPM can be a challenge! 

That's why NewYorkBIO is pleased to offer our members complimentary meeting space during the 34th Annual JP Morgan Healthcare Conference in San Francisco, Jan 11-12, 2016.  Meeting space will be available on Monday, Jan 11 and Tuesday, Jan 12, from 9:00AM-5:00PM at  WeWork Golden Gate , just a short walk from Union Square.  The private meeting room features comfortable seating for you and up to five guests; free WiFi; flat-screen monitors for presentations; white boards; and complimentary beverages and snacks.  Reservations are limited and available first come, first served.

NewYorkBIO began advocating for an New York City Biotechnology Tax Credit in 2007, and we are very pleased that the credit has again been extended for two years!
For the tax year ended December 31, 2015, taxpayers that are qualified emerging technology companies (QETC), engage in biotechnologies, and meet eligibility  requirements may claim a tax credit against the New York City general corporation tax, business corporation tax, or unincorporated business tax for amounts paid or incurred for certain facilities, operations, and employee training.

Taxpayers must file by JANUARY 15, 2016.

NewYorkBIO Welcomes New Board Members
NewYorkBIO announced the appointment of Robert G. Urban, PhD, Head, Johnson & Johnson Innovation, Boston, and Hala Mirza, Vice President, Corporate Communications, Regeneron, to the association's Board of Directors.
"We are very excited to have Johnson & Johnson Innovation and Regeneron represented on the NewYorkBIO Board of Directors," said NewYorkBIO Executive Director, Nathan Tinker. "The participation of these industry leaders speaks to the massive opportunity offered by the life science industry in New York. I look forward to working with Robert and Hala, along with all our Board Members, to further expand our industry's impact in the Empire State."
"Johnson & Johnson Innovation is proud to be a very active participant in the New York life sciences community, a region which is seeing a growing number of startups, real improvements in access to capital, talent, and other critical resources," said Robert G. Urban, PhD, Head, Johnson & Johnson Innovation, Boston. "The key ingredients are coming together in New York and by working with the NewYorkBIO Board I hope to even further expedite the translation of New York-based discoveries into transformational healthcare solutions for patients."
"Regeneron and NewYorkBIO have both been vital parts of the New York life science scene for over a quarter century," said Hala Mirza, Vice President, Communications, Regeneron. "New York has significant resources in academic research, company development, and a well-trained bioscience workforce, providing all the essential elements to propel an increasingly robust healthcare ecosystem."
The NewYorkBIO Board of Directors is comprised of CEOs and senior leadership of biotech, medical device, pharmaceutical companies, academic centers, and support organizations. Its membership comes from across New York and represents every major life science cluster in the State.

EventsUpcoming Events

Sunday, January 10, 2016
4:00 PM - 7:00 PM NewYork
The Marker
San Francisco, 501 Geary St, San Francisco CA 94102

Monday, February 8 - Tuesday, February 9, 2016 
BIO CEO & Investor Conference 2016
Waldorf-Astoria Hotel, NYC
More Information Here

Sunday, February 7, 2016
5:00 PM - 8:00 PM 
Pub Night @ BIO CEO & Investor Conference

Wednesday, May 11 - Thursday, May 12, 2016  
2016 NewYorkBIO Annual Conference
10 on the Park @ Time Warner Center, NYC
  Register Here
Welcome New Members

Accutar Biotechnology Inc., Brooklyn, NY
Aesku NY, Inc., Buffalo, NY
AJES LifeSciences,LLC,  Stony Brook, NY
American Laboratory Trading, East Lyme, CT
August Research LLC,  Hartsdale, NY
Berkshire Sterile Manufacturing, Inc., Lee, MA
BioBAT, Inc., Brooklyn, NY
BioINC,  Valhalla, New York
Biologichem LLC, Amherst, NY
bioMAS Solutions,  Brooklyn, NY
BREONICS, Inc., Watervliet, NY
Celgene Corporation,  Summit, NJ
Cellectis Inc., New York, New York
Celleritas Bioscience LLC,  Brooklyn, NY
Chimeron Bio, New York, NY
Darmiyan,  New York, NY
Gilda's Club NYC, New York, NY
Immix Biopharma, NY
Kallyope, New York, NY
MagnePath USA, Inc., New York, NY
Optologix, LLC,  TX
RespireRx Pharmaceuticals Inc., Glen Rock, NJ
Rheonix, Ithaca, NY
RxC International,  Morristown, NJ
Synthetic Genomics: SGI-DNA, La Jolla, CA
TARA Biosystems, New York, NY
Translational Cell Science LLC, New York, NY

Find out more about membership
Member Spotlight:

Codagenix utilizes their breakthrough platform technology termed SAVE (Synthetic Attenuated Virus Engineering) to construct live-attenuated viral vaccines against multiple targets. All live-attenuated vaccines that are currently used in the clinic were developed using a trial-and-error based method developed in the 1880s, pre-dating the discovery of the DNA double helix.  

Codagenix presents a breakthrough approach to live-attenuated vaccine design. The SAVE platform instead relies on synthetic biology and the rational "re-design" of a target virus' entire genome to yield a vaccine strain.  This customization process uses software-based algorithms to 're-code' the genome of a target virus.  SAVE-'re-coding' results in a vaccine virus with proteins 100% identical to the target strain,  ensuring the best possible antigenic match, but possesses a genome that renders it attenuated in the host.  SAVE is an up-stream approach to vaccine construction.  The science behind the SAVE 're-design' targets a fundamental process of all viruses and thus it is viewed as platform that will yield a pipeline of candidate vaccine strains against multiple targets that include: Influenza virus, Dengue Virus, Respiratory Syncytial virus, poliovirus, and others.

MemberNewsNewYorkBIO Member News

If you have news to share with other NewYorkBIO members, please send notes or releases to
AbbVie announced the results of RESONATE™-2, a Phase 3 clinical trial in which ibrutinib significantly decreased the risk of progression or death and significantly decreased the risk of death (versus chemotherapy) in treatment-naive patients 65 years and older with chronic lymphocytic leukemia (CLL). 

Accelerator Corp
Accelerator Corporation announced the Series A financing of Petra Pharma Corporation to develop small molecule inhibitors for the treatment of cancer and metabolic diseases in alliance with Weill Cornell Medicine.
Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc., announced initiation of enrollment in the first clinical study of CVT-427, an investigational agent under development for the acute treatment of migraines.
Actinium Pharmaceuticals
Actinium Pharmaceuticals announced that the FDA has cleared the Company's IND filing for Iomab-B, and that it will proceed with the pivotal Phase 3 clinical trial.
Adjuvance Technologies Inc
Adjuvance Technologies, Inc., announced that the United States Patent and Trademark Office has granted Adjuvance co-founders a patent for a pioneering invention which provides a novel synthetic method to produce saponin adjuvants including QS-21, a leading vaccine adjuvant currently used in advanced clinical trials for infectious disease, neurodegenerative disorders and oncology.
Aerotek Scientific Inc.
Aerotek employees, contractors, friends and family members came together to participate in the inaugural Aerotek in Action volunteer day.
Airweld Inc. announced that it will have the ability to retest cylinders in our Farmingdale, NY facility with the Non-Destructive Ultrasonic Cylinder Test Equipment (UE1). 

Read More
Albert Einstein College of Medicine
Montefiore and Einstein Receive NIH Cancer Research Training Grant
Applied DNA Sciences, Inc
has completed a six-month development project funded by existing defense contracts to demonstrate the feasibility of incorporating its SigNature® DNA technology into various conductive and non-conductive silicone elastomers.

Read More
Argon Medical Devices
Argon Medical Devices, Inc. announced that the company has received clearance from the US FDA to begin marketing the CLEANER XT™ and CLEANER 15™ Rotational Thrombectomy Systems for mechanical declotting and controlled and selective in the peripheral vasculature.

ARMGO Pharma Inc
ARMGO Pharma, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation and rare pediatric disease designation to ARM210 (also known as S48168), for the treatment for Duchenne Muscular Dystrophy (DMD)
Astellas Pharma US, Inc.
Bellicum Pharmaceuticals, Inc. and Astellas Pharma Inc. announced a global license agreement, granting Bellicum rights to develop and commercialize adoptive cell therapies for tumors expressing Prostate Stem Cell Antigen (PSCA) using PSCA technology.
Read More
AXON Communications
Axon announced the hiring of two Scientific Affairs Associates and Medical Writers.
Bayer Corporation
Bayer and CRISPR Therapeutics have entered into an agreement to create a joint venture (JV) to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease.
Read More
Berkshire Sterile Manufacturing, Inc.
Berkshire Sterile Manufacturing among winners of MassEcon Economic Impact Awards.

Read More
The Biomedical Research Alliance of New York (BRANY)
HRP Consulting Group, Inc. ("HRP") will be joining BRANY (Biomedical Research Alliance of New York, LLC ("BRANY") as a separate division of the company, both companies announced today.
Read More
BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. announced that its partner Endo International plc has exercised an early opt-in for CCH to include two new potential indications.
Read More
Bristol-Meyers Squibb
Bristol-Meyers Squibb announced that the U.S. Food and Drug Administration approved Opdivo (nivolumab) injection as a single agent for the treatment of patients with BRAF V600 wild-type (WT) unresectable or metastatic melanoma.
Buffalo Niagara
BNE announced that four life sciences companies were among 11 winning companies from the 43North 2015 business idea competition who will now call Buffalo home.
Read More

Cellectis Inc.  announced the submission of a clinical trial application (CTA) to the Medicines & Healthcare products Regulatory Agency (MHRA) requesting approval to initiate UCART19 First-in-Human clinical investigation in leukemia in the United Kingdom

Celgene International 
Sàrl, a wholly-owned subsidiary of Celgene Corporation announced that REVLIMID® (lenalidomide), a cancer medicine that is administered orally, has been granted full marketing authorization by Ja pan's Ministry of Health, Labour and Welfare for use in combination with dexamethasone as a treatment for patients newly diagnosed with multiple myeloma.

Chembio Diagnostic Systems, Inc.
Chembio Diagnostics, Inc. announced plans to commercialize multiple combination DPP® Malaria Assays to identify plasmodium falciparum and other plasmodium infections.
Read More
Children's Tumor Foundation
Children's Tumor Foundation announced $15 million in federal NF research funding to the Congressionally Directed Medical Research Program-Neurofibromatosis Research Program (CDMRP-NFRP) for Fiscal Year 2016.

Read More
Cold Spring Harbor Laboratory
The  Clark Gillies Foundation presented $50,000 to Cold Spring Harbor Laboratory (CSHL) in support of the  Sarcoma Research Project on December 22, 2015. These funds will be used to support research in the lab of CSHL Associate Professor Chris Vakoc, that will look into a rare and often fatal cancer, Rhabdomosarcoma (RMS).
Read More
Columbia College of Physicians and Surgeons
Nanofiber technology developed at Columbia may improve healing of the tendon-to-bone interface, the weak link in current rotator cuff repairs.
Read More
Columbia Life Science and Technology Ventures, Columbia University
Columbia Engineering researchers have, for the first time, harnessed the molecular machinery of living systems to power an integrated circuit from adenosine triphosphate (ATP), the energy currency of life.

Read More
ConSynanceTherapeutics, Inc.
ConSynance Therapeutics entered into a research collaboration with Dr Kokkotou of Harvard Medical School/BIDMC

Read More
Covington & Burling LLP
Covington advised AstraZeneca on its acquisition of Takeda's respiratory business.
Read More
Eli Lilly & Company
Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) announced that the U.S. Food and Drug Administration (FDA) granted approval for Basaglar®

Read More
EpiBone CEO Nina Tandon featured in "Foreign Policy: 100 Global Thinkers" in FP
Read More
Gilda's Club NYC
Gilda's Club NYC announced that Gilda's Club's 20th Anniversary Benefit Gala raised more than $1.6 million for programs. 

HHMI /The Rockefeller University
Scientists at the Howard Hughes Medical Institute's Janelia Research Campus who are studying the visual system in mice have now discovered that the input received by the visual cortex is tuned to signal the orientation and direction of movement of a visual stimulus.

Read More
Immune Pharmaceuticals Corp.
Immune Pharmaceuticals Inc. (NASDAQ:IMNP) ("Immune") a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, announced it has entered into an exclusive license with Atlante Biotech SAS, to the patents and know-how for a new format of bispecific antibodies.

Read More
International AIDS Vaccine Initiative
IAVI convened expert panel discussion in NYC for World AIDS Day
Read More
Intra-Cellular Therapies, Inc
Intra-Cellular Therapies, Inc. announced initiation of enrollment for the Phase 3 clinical trials in the Company's bipolar depression program: ITI-007-401 Monotherapy and ITI-007-402 Adjunctive Therapy to Lithium or Valproate.

Read More
Kallyope Inc
Kallyope Inc. announced that it has launched with Series A financing of $44 million.

Read More
Kaneka Americas Holding
Kaneka received U.S. Food and Drug Administration (FDA) approval for Lixelle® Beta 2-microglobulin (β2M) Apheresis Column by humanitarian device exemption (HDE) (1) Lixelle® is indicated for the treatment of patients with clinically diagnosed dialysis-related amyloidosis (DRA) (2) and is the first device in the USA to treat DRA.

Lupus Research Institute
Merging Lupus Organizations raise nearly $3M at first joint gala
MetaStat, Inc.
MetaStat announced certification from the U.S. Department of Health and Human Services' Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments.
Read More
Mintz Levin
Mintz announced that it is expanding its New York office with the addition of Patricia L. Kantor and Anthony J. Viola, who join the firm's Real Estate and Litigation practices.
Read More
Morrison & Foerster LLP
Morrison & Foerster, a leading global law firm, is pleased to announce the election of 12 lawyers to the firm's partnership.
Read More
New York Blood Center, Inc
New York Blood Center (NYBC) is pleased to announce the award of several new patents in 2014/15  

Read More
NYU Tandon
NYU Tandon reports that, as of December 2015, the NYU Tandon Incubators boast a survival rate of nearly 90 percent; of 64 program graduates, 56 remain operational. This stands in sharp contrast to the typical failure rate of 80 to 90 percent for startup companies in general.
Read More
New York Genome Center
The New York Genome Center was awarded $13.5 million from the National Heart, Lung and Blood Institute (NHLBI) to conduct a Whole Genome Sequencing and Omics Project for the Trans-Omics for Precision Medicine (TOPMed) Program..
Read More
The New York Stem Cell Foundation
New York Stem Cell Foundation announced $7.5 M to five new NYSCF - Robertson Investigators making the transition from post-docs to their own labs

Read More
New York Presbyterian Hospital 
New York Presbyterian Hospital, Brigham and Women's Hospital and Columbia University Medical Center have received a four-year, $8.56 million grant from the National Institutes of Health (NIH) /National Institute for Arthritis, Musculoskeletal and Skin Diseases (NIAMS) for a new, clinical trial examining Cardiovascular Disease (CVD) in patients with Rheumatoid Arthritis
Read More
Novomer LLC
Novomer announced that Jowat AG is the first to commercially adopt Novomer's new Converge® polypropylene carbonate (PPC) polyols for use in polyurethane hot melt adhesive applications.

Read More
Ophthotech Corporation
Opthotech announced that Glenn P. Sblendorio, a leading industry veteran, has agreed to join the Company as Executive Vice President, Chief Operating Officer and Chief Financial Officer on April 1, 2016.
Read More

Optologix LLC
Optologix, LLC (Optologix) announced today it has executed a license agreement with The University of Texas Southwestern Medical Center (UT Southwestern), providing Optologix with exclusive rights to further develop and commercialize an optogenetics-based platform technology.
Pfizer, Inc.
Pfizer acquired  the U.S. rights to Cellectis'  CAR-T asset UCART19. 

Progenics Pharmaceuticals Inc.
Progenics Pharmaceuticals, Inc. leased 26.5K feet of office space in One World Trade Center .
Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc. and Sanofi announced that UnitedHealth Group will provide preferred access to Praluent Injection through OptumRx and UnitedHealthcare for Commercial, Medicare, and Managed Medicaid patients.
Relmada Therapeutics
Relmada Therapeutics, Inc. announced that James Dolan, formerly Senior Vice President of Licensing and Business Development at Purdue Pharma L.P., has joined Relmada as an advisory partner.
The Research Foundation of SUNY
Governor Andrew M. Cuomo announced the opening of the final phase of SUNY Downstate Medical Center's Biotechnology Incubator at 760 Parkside Avenue in Brooklyn. The 26,000-square-foot addition will double the size of the current facility.
Rheonix Inc. raised $28.6 million to further expand the company's commercialization efforts for its molecular testing platforms, the Encompass MDx® and Encompass OptimumTM.

Roche/Roche TCRC, Inc
Roche announced that the FDA granted accelerated approval to Alecensa® (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
The Rockefeller University
Luciano Marraffini, assistant professor and head of the Laboratory of Bacteriology, has been recognized with the Hans Sigrist Prize for his work developing a new approach to combat antibiotic resistance.
Signal Genetics, Inc.
Signal Genetics, Inc., announced that the Company has entered into an agreement with the University of Texas MD Anderson Cancer Center to further validate the clinical utility of its MyPRS ® test for multiple myeloma.
Sophie Davies School of Biomedical Education City College
Associate Professor of Biomedical Engineering Susannah Fritton of the Grove School of Engineering and Associate Professor of Biology Anuradha Janakiraman of the Division of Science are the first recipients of the Harvey L. Karp '49 Discovery Award in the Sciences, which provides $50,000 in seed funding for novel and high-risk research.

St. John's University Institute for Biotechnology
Vijaya L. Korlipara, Ph.D., Professor of Pharmaceutical Sciences and Director of the Institute for Biotechnology at St. John's University, has been named a Fellow of the American Chemical Society.

Target Health
Digitana engaged Target Health as its CRO, using its web-based eSource-enable EDC system to collect direct data entry from patients. According to Target Health, this is the first product to be approved using in its pivotal trial, direct data entry of patient data at the time of the clinic visit into an EDC system, with no need for paper records.

Tetragenetics, Inc.
Tetragenetics Inc., an emerging biotechnology company engaged in the expression of ion channel drug targets, anno unced a new partnership program for the discovery and development of therapeutic monoclonal antibodies (mAbs) directed against well-known ion channel drug targets implicated in a wide range of disease states -such as pain and autoimmune disorders.

University of Albany, SUNY
The University at Albany will offer a new degree program in bio-instrumentation, designed to address the demand for advanced instrumentation technology specialists in today's growing biomedical and biological research industry.

University of Rochester
More than 15 years of research led by neurologists at the University of Rochester Medical Center (URMC) has culminated in the first approved treatment for individuals with a rare neuromuscular disorder called periodic paralysis.   The FDA recently approved dichlorphenamide.

University of Rochester ( Dr. Phipps ), PermeaDerm, Inc. ( Dr. Woodroof ) and BioDot Inc. (Dr. Lemmo)  are collaborating to make a Temporary Skin Substitute with ANTI-SCAR capabilities.
Weill Cornell Medical College
A new test that can reveal untapped therapies for patients with advanced cancers by scanning thousands of their genes will soon be available for patients at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center.

White & Case
White & Case LLP has advised J.M. Huber Corporation  on its acquisition of the specialty chemicals producer Martinswerk GmbH, from Albemarle Corporation.

MV Lamothe, Editor | (212) 433-2623 | Editor@NewYorkBIO.orgl |